MMAC yields 337.95% · ABBV yields 3.06%● Live data
📍 MMAC pulled ahead of the other in Year 1
Combined, MMAC + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MMAC + ABBV for your $10,000?
MMA Capital Holdings, Inc. engages in investing in debt associated with renewable energy infrastructure and real estate. The company is headquartered in Baltimore, Maryland and currently employs 216 full-time employees. The firm operates through three segments: United States (U.S.) Operations, International Operations and Corporate Operations. The U.S. Operations segment consists of three business lines: Leveraged Bonds, Low-Income Housing Tax Credits (LIHTC) and Energy Capital and Other Investments. In Leveraged Bonds business line, it owns and manages bonds that finance housing and infrastructure in the United States. In LIHTC business line, it owns and manages limited partner and general partner investments in affordable housing communities in the United States. In Energy Capital and Other Investments business line, it provides project capital necessary to develop and build renewable energy systems. The company manages International Operations segment through a subsidiary, International Housing Solutions S.a r.l. (IHS).
Full MMAC Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.